Vesalio appoints VP of US sales, announces publication of “impressive” first-pass rates with Neva

2115

vesalioVesalio has today announced the appointment of a new vice president (VP) of US sales, Bob Bushok, who will oversee commercial strategy and execution for the Neva VS vasospasm launch and the expected 2023 introduction of the Neva thrombectomy platform into the US market.

Bushok will be responsible for building the US sales team and will play a pivotal role in continuing to grow the company through strategic initiatives, according to a Vesalio press release. He brings with him 20 years of sales leadership experience in the neurovascular space, from major player Medtronic to several successful start-ups, including Concentric, EV3 and Viz.ai.

In his most recent role as senior director at Viz.ai, Bushok was responsible for integrated delivery networks (IDNs), national accounts and artificial intelligence (AI) use to increase the speed of and access to care in acute ischaemic stroke.

His appointment coincides with a new clinical publication in the journal Interventional Neuroradiology relating to Vesalio’s Neva thrombectomy device. The data collected by Arsida Bajrami (Istanbul Aydın University, Istanbul, Turkey) and colleagues constitute the largest patient series to date on this technology, and underscore the device’s “excellent” first-pass rate (77%) and final recanalisation scores (modified thrombolysis in cerebral infarction [mTICI] 2b/3 of 98%), according to the company.

The paper also concludes that Neva “offers a high rate of first-pass success along with a favourable safety profile”.

“Market confidence in our technology continues to grow given the exceptional clinical results and the support of stroke specialists who have been building its reputation worldwide,” said Steve Rybka, CEO of Vesalio. “The addition of Bob Bushok to our team is a key milestone as we move into the US commercialisation phase. We are excited to have Bob lead our US sales team to further drive our global sales momentum.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here